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Central nervous system
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Background and purpose. Although chemoradiotherapy has demonstrated a survival beneﬁt in patients diagnosed of glioblastoma
(GB), majority of patients present intracraneal tumor recurrence. Radiation planning using 11C-Methionine Positron Emission
Tomography (MET-PET) may identify regions of target volume with different metabolism that may have prognostic implica-
tions. Our primary end point was to evaluate if the MET-PET initial distribution could prognose the location of recurrence in
patients with. The secondary end point of the study was to analyze the effect of trimodal image fusion (CT-MET-PET/MR) for GTV
delineation in the RT-planning process.
Materials and methods. Target volumes were outlined using trimodality image fusion. GTVMET was deﬁned as the tumor volume
in MET-PET, GTVGad was the gadolinium contrast-enhancement volume on MRI. Tumor/non-tumor ratio (T/NT) and maximum
Standard Uptake Value in MET-PET (SUVmax) were determined. Additional volume information was obtained calculating sub-
traction of GTVMET–GTVGad in order to asses the volume that exclusively MET-PET added to the deﬁnitive GTV (GTVDEF). Tumor
recurrences were delineated in the MRI/MET-PET images and co-registered with the previous GTVMET in order to delimit the ini-
tial metabolic uptake in the planning MET-PET. The association of postoperative prognostic factors and progression-free survival
was evaluated using Chi Square tests.
Results. With a median follow-up of 18.7 months, 40 patients were included in the study. MET-PET detected a median tumor
volume of 4 cm3, ranged from 0.1 cm3 to 41.3 cm3 that were not identiﬁed by MRI. The median T/NT ratio was 2.3. The recurrent
volume delineated in the MRI image correlates with the highest uptake value in the planning MET-PET in 30/40 patients (70%).
Medians PFS was 20.4 months (95% CI: 16.3–24.5), and in subjects with a higher T/NT ratio, a shorter PFS (<24 weeks) is 4.5 times
more likely (p=0.025; odds ratio: 4.5; 95% CI: 1.2–16.9).
Conclusions. MET-PET before IMRT in resected GB patients provides additional diagnostic information that can inﬂuence the GTV
delineation. MET-PET appears to identify areas at highest risk for recurrence in 70% of patients. The incorporation of MET-PET
in radiation treatment planning should be evaluated in future studies to determine the hypothetical local control beneﬁt of GB
after radiation therapy.
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Introduction. Myxopapillary ependymomas are histologically benign tumours (WHO classiﬁcation) that usually they tent a very
indolent course. However, atipical types have an aggressive evolution.
Aims. We want to warning about atypical forms can need follow-up for long time because they can metastasize.
Methods. We describe a 15-years-old patient diagnosticated of T11-L3 myxopapillary ependymoma (WHO classiﬁcation grade 1)
that was treated with surgery. After two years a new surgery was necessary for local recidive. The next year was diagnosticated
of new lesions localizated in conus medullarys. In this time, surgery and radiotherapy were realizated (5040 cGy, 180 cGy per
fraction). For 13 years the patient had no recurrence; due to this, the follow-up was ﬁnished. After 4 years the patient begins
1507-1367/$ – see front matter
